secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2024-09-05T23:59:59+00:00
Accession:  0001213900-24-075697
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix shareholders to vote on Series B conversion, $5M financing at Sept 5 meeting
--------------------------------------------------------------------------------

- Annual meeting on Sept 5, 2024; vote on conversion of 269.7M shares from Series B Preferred and $5M PMX private placement.
- Pro forma shows Series B conversion eliminates $64.2M carrying value of preferred stock and adds 269.7M common shares.
- Pro forma also reflects settlement of $5M related party debenture via 20.5M shares and PIO exercise netting $922,749.
- If approved, conversion triggers a change of control, requiring full compliance with Nasdaq initial listing criteria.
- Pro forma weighted average shares outstanding would be 325.5M vs 22.2M actual; net loss per share widens to $0.08.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024075697/0001213900-24-075697-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024075697/ea0213522-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-075697

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer